A nanoparticle inhalant for treating heart disease

A nanoparticle inhalant for treating heart disease
Artist’s rendering of nanoparticles delivering drugs directly to heart muscle fibers after being inhaled. Credit: Ella Maru studio, scientific-illustrations.com

A team of researchers from Italy and Germany has developed a nanoparticle inhalant for treating people suffering from heart disease. In their paper published in the journal Science Translational Medicine, the group describes development of the inhalant, how it was used and how well it worked when tested on lab animals.

In recent years, have been developed to deliver drugs to specific parts of the body, allowing for direct contact therapy—such remedies are typically administered orally or intravenously, which the researchers with this new effort describe as inefficient for delivery of cardiac medicines. Their approach allows for inhaling the particles, which allows them to reach the heart faster and to be taken up by cardiomyocytes, which results in improved .

The team created their nanoparticles out of material that closely resembles teeth and bone, resulting in calcium phosphate particles small enough to absorb into heart tissue, but big enough to carry medicines to where they are needed. The medicine in this instance was a drug that has been found to repair calcium channels on the surfaces of heart cells—a critical part of restoring normal cardiac electrical activity.

After loading the nanoparticles with the therapy drugs, the team administered them to mice and rats whose hearts had been damaged in a way that mimicked diabetic cardiomyopathy. The team then measured the health of their hearts by noting how much blood was ejected from the . They report that prior to administration of the drug treatment, the mice with damaged hearts scored 17 percentage points lower than healthy mice. After treatment, they found measurements rose by an average of 15 percentage points, which they describe as a near complete recovery.

A nanoparticle inhalant for treating heart disease
Heart failure patients could someday receive treatments by inhaling drug-loaded nanoparticles. Credit: Ella Maru studio, scientific-illustrations.com

Pleased with their results in rodents, the researchers tested the drug delivery system in pigs (which have a respiratory system more similar to humans), specifically looking to see how quickly it would accumulate in heart tissue—they found it did so rapidly, as expected, offering an improvement over conventional methods.

The team also reports that inhalation of the nanoparticles did not cause any toxicity in in mice or rats. More study will be needed to ensure the delivery system is safe before it can be tested in humans.


Explore further

Gene therapy improved left ventricular and atrial function in heart failure by up to 25 percent

More information: Michele Miragoli et al. Inhalation of peptide-loaded nanoparticles improves heart failure, Science Translational Medicine (2018). DOI: 10.1126/scitranslmed.aan6205

Abstract
Peptides are highly selective and efficacious for the treatment of cardiovascular and other diseases. However, it is currently not possible to administer peptides for cardiac-targeting therapy via a noninvasive procedure, thus representing scientific and technological challenges. We demonstrate that inhalation of small (<50 nm in diameter) biocompatible and biodegradable calcium phosphate nanoparticles (CaPs) allows for rapid translocation of CaPs from the pulmonary tree to the bloodstream and to the myocardium, where their cargo is quickly released. Treatment of a rodent model of diabetic cardiomyopathy by inhalation of CaPs loaded with a therapeutic mimetic peptide that we previously demonstrated to improve myocardial contraction resulted in restoration of cardiac function. Translation to a porcine large animal model provides evidence that inhalation of a peptide-loaded CaP formulation is an effective method of targeted administration to the heart. Together, these results demonstrate that inhalation of biocompatible tailored peptide nanocarriers represents a pioneering approach for the pharmacological treatment of heart failure.

Journal information: Science Translational Medicine

© 2018 Medical Xpress

Citation: A nanoparticle inhalant for treating heart disease (2018, January 18) retrieved 22 October 2019 from https://medicalxpress.com/news/2018-01-nanoparticle-inhalant-heart-disease.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1194 shares

Feedback to editors

User comments

Jan 18, 2018
Damaged heart muscle requires calcium to contract but too much calcium causes death of the heart cells and a little too much over time results in calcification of the arteries and tissues. These nanoparticles may be good but may also be very bad in the long haul for these types of cases. I would not put my money into this endeavor especially when stem cells are available and working well for these cases already.

Jan 18, 2018
"The team also reports that inhalation of the nanoparticles did not cause any toxicity in heart tissue in mice or rats."

What about damage in the rest of the rat?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more